S&P Futures
4,058.25 +2.50 (+0.06%) Dow Futures
32,607.00 +7.00 (+0.02%) Nasdaq Futures
12,274.75 -4.50 (-0.04%) Russell 2000 Futures
1,839.20 +2.90 (+0.16%) Crude Oil
113.90 -0.19 (-0.17%) Gold
1,853.20 +5.60 (+0.30%)
Forte Biosciences, Inc. (FBRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.2200 |
| Open | 1.2500 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1000 |
| Day's Range | 1.1700 - 1.2900 |
| 52 Week Range | 1.0300 - 43.5700 |
| Volume | |
| Avg. Volume | 170,901 |
| Market Cap | 18.009M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3570 |
| Earnings Date | May 16, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for FBRX
Related Research
- Forte Biosciences, Inc.Analyst Report: Incyte Corp.Founded in 1991 and based in Wilmington, Delaware, Incyte is a drug discovery and development company. The company has several small-molecule compounds in clinical trials, while its primary revenue-generating products include Jakafi, Iclusig, Pemazyre, and Olumiant. Jakafi treats polycythemia vera (PV), a type of blood cancer; myelofibrosis (MF), a rare bone marrow disorder; and steroid-refractory acute graft-versus-host-disease (GVHD), while Iclusig treats leukemia, Pemazyre treats bile duct cancer, and Olumiant treats rheumatoid arthritis. The company also recently launched Tabrecta, for non-small-cell lung cancer, and has several active Phase 2 and 3 programs in oncology.RatingFair ValueEconomic Moat18 hours agoArgus Research
- Business Wire
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
DALLAS, May 16, 2022--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2022 results and provided a business update.
- Simply Wall St.
Here's Why We're Watching Forte Biosciences' (NASDAQ:FBRX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. – FBRX
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. (“Forte” or the “Company”) (NASDAQ: FBRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Forte and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class acti
